N4382

Nalidixic acid sodium salt

powder

• Synonym(s): 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid sodium salt
• Empirical Formula (Hill Notation): C₁₂H₁₁N₂NaO₃
• CAS Number: 3374-05-8
• Molecular Weight: 254.22
• Beilstein: 3580062
• EC Number: 222-159-7
• MDL number: MFCD00064376
• PubChem Substance ID: 24278589
• NACRES: NA.77

Properties

• form: powder
• Quality Level: 200
• antibiotic activity spectrum: Gram-negative bacteria; Gram-positive bacteria
• Mode of action: DNA synthesis | interferes; enzyme | inhibits
• originator: Sanofi Aventis
• SMILES string: [Na+].CCN1C=C(C([O-])=O)C(=O)c2ccc(C)nc12
• InChI: 1S/C12H12N2O3.Na/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14;/h4-6H,3H2,1-2H3,(H,16,17);/q;+1/p-1
• InChI key: ROKRAUFZFDQWLE-UHFFFAOYSA-M

Description

General description

Chemical structure: quinolone

Packaging

1, 5, 25, 100 g in glass bottle

Biochem/physiol Actions

Nalidixic acid sodium salt is an inhibitor of bacterial DNA polymerase (DNA gyrase) and avian myeloblastoma virus reverse transcriptase. Inhibits nucleic acid and protein synthesis in Saccharomyces cerevisiae.

Features and Benefits

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Safety Information

• Pictograms: GHS07,GHS08
• Signal Word: Warning
• Hazard Statements: H302 - H351
• Precautionary Statements: P202 - P264 - P270 - P280 - P301 + P312 - P308 + P313
• Hazard Classifications: Acute Tox. 4 Oral - Carc. 2
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves